Mercaptopurine (6-MP)

CAS No. 50-44-2

Mercaptopurine (6-MP)( 6-MP )

Catalog No. M14718 CAS No. 50-44-2

Mercaptopurine (6-mercaptopurine; 6-MP) is an immunosuppressive drug.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 48 In Stock
25MG 29 In Stock
50MG 43 In Stock
100MG 61 In Stock
200MG Get Quote In Stock
500MG 77 In Stock
1G 111 In Stock

Biological Information

  • Product Name
    Mercaptopurine (6-MP)
  • Note
    Research use only, not for human use.
  • Brief Description
    Mercaptopurine (6-mercaptopurine; 6-MP) is an immunosuppressive drug.
  • Description
    Mercaptopurine (6-mercaptopurine; 6-MP) is an immunosuppressive drug; is a thiopurine.(In Vitro):6-Mercaptopurine hydrate (6-MP) induces NR4A3 transcriptional activity 1.6- to 11-fold (P<0.01) in a dose-responsive manner. It is found that 6-Mercaptopurine hydrate leads to a dose-dependent increase in NR4A3 protein levels. 6-MP treatment increases cell surface GLUT4 in both basal cells 1.8- to 3.6-fold (P<0.01) and insulin-stimulated cells 2.9- to 4.4-fold (P<0.01) over that in controls. It is also found that 6-Mercaptopurine hydrate increases phospho-AS160 significantly in a dose-responsive manner under both basal and insulin-stimulated conditions.(In Vivo):In the fetal telencephalons of the 6-Mercaptopurine hydrate (6-MP)-treated group, the S phase cell population increases at 36 and 48 h and returns to the control level at 72 h after treatment. The G2/M phase cell population begins to increase at 24 h, peaks at 36 h, decreases at 48 h, and finally returnes to the control level at 72 h. On the other hand, the sub-G1 phase cell population (apoptotic cells) begins to increase at 36 h, peaks at 48 h, and then decreases at 72 h.
  • In Vitro
    6-Mercaptopurine hydrate (6-MP) induces NR4A3 transcriptional activity 1.6- to 11-fold (P<0.01) in a dose-responsive manner. It is found that 6-Mercaptopurine hydrate leads to a dose-dependent increase in NR4A3 protein levels. 6-MP treatment increases cell surface GLUT4 in both basal cells 1.8- to 3.6-fold (P<0.01) and insulin-stimulated cells 2.9- to 4.4-fold (P<0.01) over that in controls. It is also found that 6-Mercaptopurine hydrate increases phospho-AS160 significantly in a dose-responsive manner under both basal and insulin-stimulated conditions.
  • In Vivo
    In the fetal telencephalons of the 6-Mercaptopurine hydrate (6-MP)-treated group, the S phase cell population increases at 36 and 48 h and returns to the control level at 72 h after treatment. The G2/M phase cell population begins to increase at 24 h, peaks at 36 h, decreases at 48 h, and finally returnes to the control level at 72 h. On the other hand, the sub-G1 phase cell population (apoptotic cells) begins to increase at 36 h, peaks at 48 h, and then decreases at 72 h.
  • Synonyms
    6-MP
  • Pathway
    Metabolic Enzyme/Protease
  • Target
    Dehydrogenase
  • Recptor
    IMPDH| HPRT
  • Research Area
    Other Indications
  • Indication
    ——

Chemical Information

  • CAS Number
    50-44-2
  • Formula Weight
    152.18
  • Molecular Formula
    C5H4N4S
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO: 30 mg/mL (197.13 mM)
  • SMILES
    S=C1NC=NC2=C1NC=N2
  • Chemical Name
    1H-purine-6(7H)-thione.

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Dubinsky MC, et al. Clin Gastroenterol Hepatol. 2004 Sep;2(9):731-43.
molnova catalog
related products
  • DHODH-IN-12

    DHODH-IN-12 is a leflunomide derivative and a weak dihydrorotate dehydrogenase (DHODH) inhibitor with a pKa of 5.07.

  • AG-636

    AG-636 is a potent, reversible, selective and orally active DHODH inhibitor(IC50 of 17 nM). It has strong anticancer effects.

  • CB29

    CB29 is a specific inhibitor of aldehyde dehydrogenase 3A1 (ALDH3A1).